Book chapter
Use of Colistin in Critically Ill Patients
Polymyxin Antibiotics: From Laboratory Bench to Bedside, pp 155-179
31 Jul 2019
PMID: 31364078
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Due to lack of better therapeutic options, colistin use for extensively drug-resistant Gram-negative organisms was revived in the past two decades, including in patients in intensive-care units (ICU). There are multiple knowledge gaps pertaining to the clinical use and utility of colistin in critically-ill patients, but due to lack of options, it is used in these high risk patients. In this chapter, we critically review the various topics pertaining to colistin use in critically-ill patients, while highlighting the (lack of) controlled evidence supporting common current practices pertaining to colistin use by clinicians.
Metrics
Details
- Title
- Use of Colistin in Critically Ill Patients
- Creators
- Dror Marchaim - Assaf Harofeh Medical CenterDonald Kaye - Drexel UniversityKeith S. Kaye - University of Michigan–Ann Arbor
- Publication Details
- Polymyxin Antibiotics: From Laboratory Bench to Bedside, pp 155-179
- Series
- Advances in Experimental Medicine and Biology
- Publisher
- Springer International Publishing; Cham
- Resource Type
- Book chapter
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000500478800013
- Scopus ID
- 2-s2.0-85070514308
- Other Identifier
- 991019168431404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Medicine, Research & Experimental
- Pharmacology & Pharmacy